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Background & Aims: The role of the intestine in the maintenance of cholesterol homeostasis is 
increasingly recognized. Fecal excretion of cholesterol is the last step in the atheroprotective 
reverse cholesterol transport pathway, to which biliary and transintestinal cholesterol excretion 
(TICE) contribute. The mechanisms controlling the flux of cholesterol through the TICE pathway 
are, however, poorly understood. We aimed to identify mechanisms that regulate and 
stimulate TICE. 
 
Methods: We performed studies with C57Bl/6J mice, as well as mice with intestine-specific 
knockout of the farnesoid X receptor (FXR), mice that express an FXR transgene specifically in 
the intestine, and ABCG8-knockout mice. Mice were fed a control diet or a diet supplemented 
with the FXR agonist PX20606, with or without the cholesterol absorption inhibitor ezetimibe. 
Some mice with intestine-specific knockout of FXR were given daily injections of fibroblast 
growth factor (FGF)19. To determine fractional cholesterol absorption, mice were given 
intravenous injections of cholesterol-D5 and oral cholesterol-D7. Mice were given 13C-acetate in 
drinking water for measurement of cholesterol synthesis. Bile cannulations were performed 
and biliary cholesterol secretion rates were assessed. In a separate set of experiments, bile 
ducts of male Wistar rats were exteriorized, allowing replacement of endogenous bile by a 
model bile. 
 
Results: In mice, we found TICE to be regulated by intestinal FXR, via induction of its target 
gene Fgf15 (in mouse; FGF19 in rat and human). Stimulation of this pathway caused mice to 
excrete up to 60% of their total cholesterol content each day. PX20606 and FGF19 each 
increased the ratio of muricholate:cholate in bile, inducing a more hydrophilic bile salt pool. 
The altered bile salt pool stimulated robust secretion of cholesterol into the intestinal lumen via 
the sterol-exporting heterodimer ATP binding cassette subfamily G member 5/8 (ABCG5/G8). 
Of note, the increase in TICE induced by PX20206 was independent of changes in cholesterol 
absorption. 
 
Conclusions: Hydrophilicity of the bile salt pool, controlled by FXR and FGF15/19, is an 
important determinant of cholesterol removal via TICE. Strategies that alter bile salt pool 
composition might be developed for prevention of cardiovascular disease. 
 
 

















The role of the liver in the maintenance of cholesterol homeostasis is well established. By serving as a 
major site of cholesterol synthesis, lipoprotein production and uptake, and catabolism of cholesterol 
through bile salt synthesis as well as by secretion of vast amounts of sterols into the bile, the liver acts as 
chief regulator of cholesterol metabolism.1 More recently, it has become clear that the intestine also 
plays an eminent role in the control of the body’s cholesterol balance by mechanisms beyond control of 
cholesterol absorption.2,3 We4 and others5,6  recently showed that, in addition to removal from the body 
via biliary sterol secretion, cholesterol can also be transported directly from blood into the intestinal 
lumen preparatory to its excretion with the feces. This pathway is now known as transintestinal 
cholesterol excretion or TICE.7,8 Under standard laboratory conditions, this pathway accounts for 
approximately 30% of fecal neutral sterol (i.e., cholesterol and its bacterial derivatives) output in mice. 
Despite its evident importance in control of cholesterol homeostasis, the molecular mechanisms and 
control of TICE have remained largely elusive. We have demonstrated that cholesterol excretion via the 
TICE pathway can be stimulated by liver X receptor (LXR)-agonism and by plant sterols, indicating a 
regulatory role for the sterol transporting heterodimer ATP binding cassette subfamily G member 5/8 
(ABCG5/G8).4,9 In addition, Le May et al. suggested a role for the multidrug transporter ATP-binding 
cassette, sub-family B (MDR/TAP), Member 1 (ABCB1) and proposed regulatory activities by proprotein 
convertase subtilisin/kexin type 9 (PCSK9).5 More recently, flavin monooxygenase 3 (FMO3) has been 
implicated in TICE regulation.10  
Cholesterol serves as substrate for the production of steroid hormones but is also indispensable for bile 
salt synthesis in the liver. Following biliary secretion, bile salts enter the intestinal lumen where their 
presence is essential for cholesterol absorption to occur.11 A considerable number of different bile salt 
species is normally present within a single individual. The physical-chemical characteristics of bile salts 















Chiang13 for recent reviews), thereby permitting metabolic control via regulation of the bile salt pool 
composition. The farnesoid X receptor (NR1H4/FXR) is the central actor controlling bile salt synthesis 
and is expressed mainly in the liver and small intestine.14-16 Intestinal FXR has been shown to play a 
pivotal role in regulating hepatic bile salt synthesis and bile salt pool composition through promoting the 
production of fibroblast growth factor 15 (FGF15; FGF19 in humans) that inhibits bile salt synthesis in 
the liver.17  
In the present study, we reveal that agonism of intestinal FXR greatly enhances the flux of cholesterol 
through the TICE pathway in a manner that largely depends on ABCG5/G8 function in the intestine. The 
composition of the bile salt pool conceivably impacts the rate of cholesterol removal from the body via 
TICE. Our data strongly suggests that a high proportion of hydrophilic bile salts stimulates this route via 
activation of ABCG5/G8 in the intestine. Importantly, the magnitude of the increase in TICE induced by 
FXR agonism remained similar under conditions in which cholesterol absorption was blocked by 
ezetimibe. This demonstrates that decreased cholesterol absorption is not the mechanism by which 
fecal neutral sterol excretion is stimulated upon FXR activation but that the flux of cholesterol into the 
















MATERIALS AND METHODS 
 
Animal experiments 
Male age-matched wild-type (WT) C57Bl/6J mice, intestine-specific FXR knock-out (iFXR KO)18 and their 
WT littermates, intestine-specific FXR-transgenic mice (iFXR TG; see supplemental materials and 
methods) and their non-transgenic littermates (FXR KO)19 as well as ABCG8 knock-out (ABCG8 KO) mice 
and their WT littermates20 were housed in a light (12:12)- and temperature-controlled (21°C) facility and 
received standard rodent diet (RMH-B, Hope Farms, Woerden, The Netherlands) ad libitum. When 
stated, mice received 10 mg/kg/day PX20606 (PX) (Phenex Pharmaceuticals, AG, Heidelberg, 
Germany)21,22, 0.005% (w/w) ezetimibe  (Ezetrol; Pharmacy UMCG, Groningen, The Netherlands), or 
both compounds mixed into their diet. Additionally, ABCG8 KO mice were injected with 1 x 1011 
particles/mouse of an Abcg8-encoding adenovirus (AdABCG8) or control virus (AdNull) and experiments 
were performed between day 3 and day 5 after administration. Furthermore, iFXR KO mice were 
injected (i.p) with 1 mg/kg/day FGF19 (generous gift of dr. J. Nguyen, NGM Biopharmaceuticals San 
Francisco, USA) for 8 consecutive days when indicated. Experiments were conducted in conformity with 
the law on the welfare of laboratory animals and experimental procedures were approved by the 
responsible ethics committees. 
 
Experimental procedures 
To determine fractional cholesterol absorption, mice received an intravenous dose of 0.3 mg 
cholesterol-D5 (Medical Isotopes, Inc, Pelham, NH, USA) dissolved in Intralipid (20%, Fresenius Kabi, Den 
Bosch, The Netherlands) and an oral dose of 0.6 mg cholesterol-D7 (Cambridge Isotope Laboratories, 















Mice received 13C-acetate via the drinking water 3 days prior to the end of the experiment in order to 
determine cholesterol synthesis. At the end of the experiment, mice were anesthetized and bile 
cannulation was performed.23 In a separate series of experiments male Wistar rats (Sulzfeld, Germany) 
were surgically equipped with permanent cannulas in their bile duct and duodenum.24 The outlets of the 
cannulas were fixed on the head of the animals. After surgery, the animals were allowed to recover for 5 
days. During this period, the cannulas from the bile duct and duodenum were connected to each other 
on the head of the animals, essentially restoring the enterohepatic circulation via an extended bile duct. 
After having obtained feces for determination of fecal neutral sterol (FNS) excretion, the enterohepatic 
circulation was interrupted and all bile of the rats was quantitatively collected in a tube located outside 
the cage. From the moment of interruption, model bile was infused into the intestinal cannula. All 
animals received identical model bile composed of 15 mM taurocholic acid and 2.5 mM 
phosphatidylcholine at a rate of 1.2 mL/hour. PX20606 (10 mg/kg/day) was provided via the diet when 
indicated, starting two weeks before interruption of the enterohepatic circulation.  
Analytical procedures 
Plasma triglycerides, total cholesterol and free cholesterol were determined using commercially 
available kits (Roche Diagnostics, Mannheim, Germany and DiaSys Diagnostic Systems, Holzheim, 
Germany) or using gas chromatography after trimethylsilylation as described below. Biliary cholesterol 
was quantified by gas chromatography as described below for measurement of fecal neutral sterols.25 
Biliary and fecal bile salt composition were quantified using capillary gas chromatography as described.26 
The hydrophobicity index of the bile salt pool was calculated according to Heuman.27 Fecal cholesterol 
and its derivatives were trimethylsilylated with pyridine, N,O-Bis (trimethylsilyl) trifluoroacetamide and 
trimethylchlorosilane and measured with gas chromatography. Cholesterol label enrichment was 
determined by capillary gas chromatography on a Agilent gas chromatograph (7890A; Amstelveen, The 















Bis (trimethylsilyl) trifluoroacetamide containing 1% trimethylchlorosilane. Isotope ratios were 
determined in the selected ion monitoring mode on m/z 458 (M0) to 465 (M7). Cholesterol absorption 
and synthesis were calculated as described elsewhere.4,9,28 TICE was calculated by subtracting the 
contribution of dietary and biliary cholesterol to fecal neutral sterols after correcting for absorption 
according to the formula TICE=FNS-((Choldiet+Cholbile)*(1-Fa)), where FNS is fecal neutral sterols and Fa is 
fractional cholesterol absorption.28  
 
RNA isolation and measurement of mRNA levels by quantitative real-time PCR 
Total RNA was isolated using TRI-Reagent (Sigma, St. Louis, MO, USA). cDNA was produced using 
Moloney-Murine Leukemia Virus reverse transcriptase (Life Technologies, Bleiswijk, The Netherlands). 
Real-time qPCR analysis was performed on a 7900HT Fast Real-Time PCR system (Applied Biosystems, 
Darmstadt, Germany) and gene expression levels were normalized to 36B4. 
 
Western blotting for ABCG5 protein expression 
Intestinal brush border membranes were isolated as described by Schmitz et al.29 Equal amounts of 
brush border membranes (10 µg protein) for detection of ABCG5 were electrophoresed and blotted on 
Hybond ECL membranes (Amersham, Little Chalfont, UK). Membranes were incubated with anti-ABCG5 
primary antibody.30 Immune complexes were visualized using horseradish peroxidase-conjugated goat 
anti-rabbit (DAKO, Heverlee, Belgium) and SuperSignal West Dura substrate (ThermoScientific, Rockford, 
















Statistical analysis was performed by Kruskal-Wallis H test followed by Conover post-hoc comparisons 
using Brightstat.31 Correlations were analyzed by Spearman’s correlation using Graphpad Prism. 

















Pharmacological activation of intestinal FXR markedly enhances fecal neutral sterol excretion in mice 
To delineate the role of bile salts in control of body cholesterol fluxes, we chose to modify bile salt 
synthesis and pool composition via modulation of the activity of the bile salt-activated nuclear receptor 
FXR. C57BL/6J mice were treated with the FXR agonist PX20606 (PX) for two weeks. In line with data 
obtained in hyperlipidemic mice and monkeys22, the compound was well-tolerated and had no effect on 
body weight or food intake (data not shown). PX treatment decreased plasma cholesterol and 
triglycerides (Figure 1A,B) but increased hepatic levels of these lipids (Figure S1A,B). In keeping with the 
regulatory role of FXR in bile salt synthesis, PX treatment decreased fecal bile salt output (Figure 1C) 
which, in steady state conditions, reflects hepatic bile salt production. Furthermore, PX treatment 
strongly increased fecal neutral sterol (FNS) excretion (Figure 1D). Stably labeled cholesterol tracers 
were used to investigate the effects of PX on cholesterol absorption. Fractional cholesterol absorption 
was reduced in mice treated with the FXR agonist (Figure 1E). To explore whether decreased cholesterol 
absorption contributed to the augmented cholesterol removal with the feces, ezetimibe was added to 
the treatment regimen of the mice. Ezetimibe is a potent inhibitor of cholesterol absorption (Figure 1E) 
and therefore enabled us to study the absorption-independent effects of PX. Combination treatment of 
ezetimibe and PX led to an additional decrease in plasma lipid levels (Figure 1A,B and S1C,D). 
Interestingly, ezetimibe given in combination with PX led to a FNS excretion that was at least equal to 
the sum of both individual treatments, generating a very high rate at which cholesterol was removed 
from the body (Figure 1D). Of note, about 8 days of PX treatment were needed to reach maximal effects 
on FNS excretion, while the maximal effect of ezetimibe was established much earlier (Figures 1F and 
S2). Bile flow was doubled in PX-treated mice and this was not affected by co-treatment with ezetimibe 















PX, biliary bile salt secretion was not altered due to the increased bile flow (Figure 2B). Treatment of 
mice with the FXR agonist caused an increase of biliary cholesterol secretion while ezetimibe hardly 
impacted this flux (Figure 2C). When FNS excretion, dietary cholesterol intake, biliary cholesterol 
secretion and fractional cholesterol absorption are known, TICE can be calculated. Cholesterol removal 
via TICE was 142 µmol/day/100g body weight (>17-fold) higher in PX-treated mice compared to 
untreated controls (Figure 2D). PX treatment in combination with ezetimibe led to an increase of TICE 
with 238 µmol/day/100g compared to mice receiving ezetimibe only, indicating that PX indeed operates 
via a different mechanism as ezetimibe. Analysis of cholesterol tracer kinetics revealed that PX 
stimulated elimination of intravenously injected cholesterol-D5 from the plasma compartment (Figure 
2E). Notably, analysis of tracer within the feces revealed that PX-treated mice had excreted 68% of i.v. 
injected tracer into the feces at 72 h after injection whereas this was only 7.8% in control mice (Figure 
2F), indicating that cholesterol extracted from the plasma compartment indeed ended up in feces. 
Treatment with PX and ezetimibe caused the strongest excretion of tracer (85% of the injected dose). 
To verify the selectivity and specificity of PX, we also performed experiments in whole-body FXR knock-
out mice. PX did not impact FNS excretion (Figure S3) in these mice nor any of the other parameters 
studied, confirming that the observed effects were indeed mediated through FXR.  
 
The role of intestinal FXR in control of cholesterol fluxes 
PX has been shown to activate both hepatic and intestinal FXR.22 To disentangle the effects of hepatic 
and intestinal FXR, we performed experiments in intestine-specific FXR (iFXR) KO mice. Interestingly, the 
PX-induced changes in cholesterol fluxes were almost completely abrogated in these mice; only 
marginal inductions of FNS excretion (Figure 3A) and TICE (Figure 3B) were observed and, in contrast to 















3C). This indicates that intestinal FXR plays a major role in the control of whole-body cholesterol 
turnover. To more clearly delineate the role of intestinal FXR in control of cholesterol fluxes, we rescued 
intestinal FXR expression in a total body FXR KO background. Transgenic intestine-specific FXR 
expressing mice (iFXR TG) were generated using the murine FXR gene under control of the villin 
promoter (Figure S4). No overt phenotypic differences between FXR KO and iFXR TG mice were noticed 
when kept under standard laboratory conditions. Treatment of iFXR TG mice with PX did not reduce 
plasma cholesterol and triglyceride levels (Figures 4A,B). This suggests that hepatic FXR rather than 
intestinal FXR mediates the reduction of plasma lipids in response to PX. The compound also did not 
affect liver weight and biliary cholesterol secretion (data not shown). Reinstitution of intestinal FXR 
expression in FXR KO mice did, however, restore the PX-induced increase in FNS excretion and TICE 
substantially (Figure 4C,D). Together, these data highlight the critical role of intestinal FXR in the 
stimulation of cholesterol removal via TICE upon treatment with PX. Furthermore, fractional cholesterol 
absorption (Figure 4E) and fecal bile salt output (Figure 4F) were decreased in response to PX treatment 
in iFXR TG mice. 
  
Transport of cholesterol from enterocytes into the intestinal lumen 
Next, we addressed the mechanism via which cholesterol is secreted into the intestinal lumen. Being an 
established cholesterol transporter present at the luminal side of enterocytes, the ABCG5/G8 
heterodimer is a potential mediator of the TICE pathway. PX increased Abcg5/g8 expression in the liver 
but had no effect in the small intestine whereas ezetimibe slightly increased hepatic expression of 
Abcg5/g8 but decreased the expression in the proximal small intestine (Figure 5A). The effect on 
intestinal gene expression was mirrored at protein level (Figure 5A, right panel). Since expression levels 















involved in stimulation of FNS excretion and TICE by PX using ABCG8 KO mice. Single ABCG8 knock-out 
mice phenocopy ABCG5/G8 double knock-outs because the proteins need to dimerize to allow 
trafficking of the transporter to the apical membrane of hepatocytes and enterocytes.32 We challenged 
ABCG8 KO mice and WT littermates with PX either or not in combination with ezetimibe and assessed 
the effects on body cholesterol fluxes. Severely blunted inductions of FNS excretion (Figure 5B, left 
panel) and TICE (Figure 5C, left panel) in response to treatment with PX or PX/ezetimibe clearly 
demonstrate that ABCG5/G8 is mediating the vast majority of cholesterol that is secreted via the TICE 
pathway under these stimulated conditions. In conformity with the established role of ABCG5/G8 
regarding secretion of hepatic cholesterol into the bile, the PX-induced increase in biliary cholesterol 
secretion was absent in ABCG8 KO mice (Figure 5D, left panel). Interestingly, despite the blunted 
induction of FNS excretion, PX and dual treatment did considerably impact plasma cholesterol levels 
(Figure 5E, left panel), suggesting that the decrease of plasma cholesterol induced by PX is not merely 
the consequence of increased intestinal excretion. ABCG5/G8 is expressed in the liver and intestine. 
Therefore, reintroduction of ABCG8 in the liver by adenoviral transfection in ABCG8 KO mice allows the 
investigation of the effects of ABCG5/G8 deficiency specifically in the intestine. Using this model, we 
investigated the impact of intestinal ABCG5/G8 on cholesterol fluxes in response to PX and 
PX/ezetimibe. Adenoviral rescue of hepatic ABCG8 expression in ABCG8 KO mice had very little impact 
on FNS excretion, TICE and plasma cholesterol levels despite a restoration of biliary cholesterol secretion 
(Figure 5B-E, right panels). These data pinpoint intestinal ABCG5/G8 as the transporter mediating most 
of the cholesterol excretion in mice treated with either PX alone or PX/ezetimibe. 
 















FXR is expressed throughout the small intestine but is considered to act under physiological conditions 
mainly via bile salt signaling in the distal part of the ileum. Yet, PX may activate FXR all along the small 
intestine and thereby stimulate TICE at the site where it is most active, i.e., in the proximal small 
intestine.7 To analyze which genes/pathways were targeted by PX, we performed microarray analysis in 
the proximal intestine at an FDR of 5%. Figure S5A shows the results for Kyoto encyclopedia of genes 
and genomes (KEGG) pathway analysis; genes involved in Parkinson’s disease, Huntington disease and 
oxidative phosphorylation came up in the proximal part of the small intestine. KEGG pathway analysis of 
the array data derived from the distal small intestine gave a very different pattern (Figure S5B) with 
nitrogen metabolism being the most regulated pathway. In contrast, cholesterol synthesis was the most 
prominently regulated pathway in the liver, indicating that the mobilized cholesterol was replenished at 
least in part by the de novo synthesis in the liver (Figure S5C).  
Validation by PCR confirmed the results of the KEGG pathway analysis in liver pointing towards 
increased cholesterol synthesis, and showed the downregulated expression of sterol 12-alpha-
hydroxylase (Cyp8b1) and cholesterol 7-alpha-hydroxylase (Cyp7a1) as a consequence of FXR agonism 
(Figure S5D). Application of mass isotopomer distribution analysis after administration of 13C-acetate 
indeed demonstrated augmented cholesterol synthesis in response to PX treatment, which was further 
induced when mice were co-treated with ezetimibe (Figure 6A). In the small intestine, FXR activation 
induced the expected upregulation of Fgf15 (Figure S6A) which is thought to mediate most of the 
physiological relevant effects of intestinal FXR on the liver. When FGF15 mediates the effects of PX on 
FNS excretion and TICE, treatment with FGF15/19 should at least partially rescue the lack of effect of PX 
in iFXR KO mice. Therefore, PX-treated iFXR KO mice were challenged for eight days with the human 
orthologue FGF19 and FNS output was compared to mice only receiving PX. As evident from the data 
shown in Figure 6B, FGF19 rescued FNS excretion thereby identifying FGF15/19 as a crucial factor 















underlying the restoration of PX-induced stimulation of FNS excretion by FGF15/19. Both PX and FGF15 
control bile salt synthesis but via differential effects on expression of Cyp7a1 and Cyp8b1 (Figures 6C 
and S6B), leading to an altered balance between the cholate and chenodeoxycholate/muricholate 
synthesis pathways. We therefore determined bile salt species composition in the iFXR KO mice treated 
with PX and/or FGF19 (Figure 6D). Interestingly, FGF19 seemed to be required for the shift of the 
balance towards the relatively hydrophilic muricholates instead of the more hydrophobic cholate and 
deoxycholate. This interesting observation let us to study the relationship between the hydrophobicity 
index (HI) of biliary bile salts, calculated according to Heuman27, and FNS excretion. A clear negative 
correlation emerged (Figure 6E), suggesting that hydrophilic bile salts stimulate FNS excretion via the 
TICE pathway. Of note, the hydrophilicity of the fecal bile salt pool changed steadily over a period of 8 
days during PX treatment (Figure S7), in line with the gradual increase in FNS (see Figure 1F). In ABCG8 
KO mice the changes in the bile salt pool composition were similar to those observed in WT mice (Figure 
6F). This translated into only minute effects on FNS excretion and TICE (Figure 5B,C), suggesting a 
functional interaction of hydrophilic bile salts with the ABCG5/G8 transporter in the intestine. 
If hydrophilic bile salts would indeed be responsible for the increased FNS excretion as a result of 
increased TICE, PX would fail to stimulate FNS excretion in bile-diverted animals. However, cholesterol 
excretion via TICE requires the presence of acceptor particles (i.e., bile salt and phospholipid micelles) in 
the intestine.7 Therefore, we used rats with exteriorized bile ducts24 that were treated with either 
vehicle or PX. Small bile samples taken from the still intact enterohepatic circulation revealed that PX 
treatment in rats also led to an increase in the relative abundance of hydrophilic muricholates (Figure 
7A). Analysis of the feces obtained at this stage revealed that PX indeed stimulated FNS excretion in 
these animals (Figure 7B). Next, the enterohepatic circulation was interrupted and long-term bile 
diversion combined with model bile infusion was performed under non-anaesthetized conditions. All 















identical bile salt actions in the intestine. If PX would mediate its effects by affecting the bile salt pool 
composition, the effects would be lost after interruption of the enterohepatic circulation and start of 
the model bile infusion. Indeed, the PX-induced stimulation of FNS excretion was completely abrogated 
when the enterohepatic circulation was interrupted and the rats were receiving the identical model bile 
(Figure 7B). Of note, gene expression analysis confirmed upregulation of Fgf19 in the ileum as well as 
enhanced hepatic expression of small heterodimer partner (Nr0b2/Shp) along with downregulation of 
Cyp7a1 and Cyp8b1 in the PX-treated rats, indicating that the FXR agonist was functionally active in the 
















In this study we demonstrate that the intestine itself has the capability to facilitate elimination 
enormous amounts of cholesterol from the body via the TICE pathway. The large capacity of TICE that 
became evident from the current studies highlights the potential of the intestine as a target for future 
cholesterol-lowering therapies. The induction of TICE in response to FXR activation appears to be 
mediated by hydrophilic bile salts. The fact that the magnitude of induction of FNS excretion and TICE by 
PX was virtually identical under conditions in which cholesterol absorption was blocked strongly 
suggests that the presence of bile salts in the intestinal lumen is not only a prerequisite for uptake of 
dietary and biliary cholesterol by the enterocytes but, additionally, an important determinant of 
excretion of plasma-derived cholesterol by the enterocytes into the intestinal lumen and hence of 
whole-body cholesterol turnover.  
The large capacity of the intestine to remove plasma-derived cholesterol becomes evident from a 
comparison between the measured values of TICE with estimates of the total amount of cholesterol that 
is present within the mouse body. The total cholesterol pool in mice has been estimated to be about 50 
mg.33 PX/ezetimibe treatment increased FNS excretion to about 30 mg per 24 hours, implying that an 
amount equal to ~60% of the entire body pool is excreted each day. Since the sum of biliary secretion 
and dietary intake of cholesterol in our experimental set up amounted to maximally 5 mg/day, TICE has 
to account for at least 25 mg/day (i.e., 80% of total cholesterol disposal) under these conditions. Earlier 
studies from our laboratories indicated that the sterol transporting heterodimer ABCG5/G8 might play a 
role in the TICE pathway.4,9,34 Our present results suggest that the physical chemical properties of 
luminal bile salts impact the activity of ABCG5/G8 at the intestinal brush border membrane and thereby 
take part in the control of TICE, at least under the TICE-stimulating conditions employed in this study. 















to 33 µmol/day/100g (15% of wild-type values), suggesting that there is another transport system 
present that can partly compensate for ABCG5/G8. In support of this, Wang et al. showed recently that 
feeding ABCG5/G8 double knock-out mice with ursodeoxycholate stimulated FNS excretion 
considerably.35 As suggested by Le May et al.5, the multidrug resistance transporter ABCB1  may be 
responsible for the ABCG5/G8-independent TICE flux or a part thereof. We did not detect increased 
intestinal expression of the Abcb1a and b genes under any of the stimulated conditions (data not 
shown). However, we also did not observe increased expression of ABCG5/G8, even under very high flux 
conditions. This indicates that this heterodimer has a very high intrinsic transport capacity. 
Whereas the synthetic FXR agonist obeticholic acid (OCA, INT-747, 6-ECDCA) closely resembles 
chenodeoxycholic acid,  PX20606 is structurally related to GW4064.21 PX was shown previously to 
potently decrease plasma cholesterol levels and progression of atherosclerosis in cholesteryl ester 
transfer protein (CETP)-transgenic/low-density lipoprotein (LDL)-receptor knock-out mice.22  At first 
sight, our results indicate that mobilization of cholesterol, driven by increased TICE, may explain the 
cholesterol-lowering effect in plasma. Indeed, plasma cholesterol was also reduced in PX-treated wild-
type mice in our study (Figure 1A). However, when increased TICE would underlie the reduction of 
plasma cholesterol levels, the same phenomenon should have been observed in the iFXR-TG mice on a 
FXR-KO background. Yet, despite a considerable rescue of TICE activity in these mice there was very little 
effect on plasma cholesterol. It is therefore most conceivable that reduction of plasma cholesterol upon 
PX treatment in mice that do express hepatic FXR is due to suppressed transcription of apolipoprotein A-
I36 and enhanced expression of scavenger receptor class B-I (SCARB1/SR-BI) upon FXR activation, as 
reported previously by others.37 In keeping with this hypothesis, we found upregulation of hepatic SR-BI 
mRNA as well as protein (data not shown). Thus, de novo cholesterol synthesis by the liver, as supported 
by a profound upregulation of Hmcgr expression and direct quantification of cholesterol synthesis using 















TICE-mediated sterol excretion. On the other hand, inspection of the effect of PX on global gene 
expression in the proximal small intestine (Figure S5A) revealed that cholesterol synthesis or transport 
were not among the most regulated pathways in KEGG analyses, suggesting that the stimulatory effect 
of PX on cholesterol trafficking was not determined by intestinal cholesterol production.  
Although the PX-induced stimulation of FNS excretion and TICE was substantial in iFXR-TG mice it was 
still considerably less when compared to wild-type mice, suggesting a role for hepatic FXR in controlling 
the rate of TICE. It was recently reported that FXR increases the hepatic response to FGF15/19, via 
stimulation of fibroblast growth factor receptor 4 (FGFR4) stability by the FXR target ß-klotho.38 This 
mechanism could potentially explain the different FNS excretion between PX-treated wild-type and 
iFXR-TG mice, which lack expression of FXR in the liver and therefore are likely less responsive to 
FGF15/19. Yet, administration of FGF19 to iFXR KO mice fully rescued the effect of PX on FNS and TICE, 
which might be due to supraphysiological plasma levels after FGF19 treatment. Indeed, FGF19 alone was 
sufficient to induce cholesterol mobilization. Studies from the group of Kliewer and Mangelsdorf 
demonstrated direct effects of this intestinal hormone on glucose, lipid and bile salt metabolism.39,40 
However, intestinal cholesterol trafficking was not addressed. The role of FGF15/19 in regulation of bile 
salt synthesis has been described in detail40 and these results are confirmed in the present study. 
Treatment with PX had a strong impact on the relative contribution of the cholate and 
chenodeoxycholate/muricholate pathways to overall bile salt synthesis in wild-type mice. Consequently, 
the ratio of muricholates to cholate in bile increased considerably. This effect of PX on bile salt species 
distribution was absent in iFXR KO mice, but was regained when FGF19 was co-administered to these 
animals. Surprisingly, although treatment with FGF19 alone did not appear to have major impact on 
CYP8B1 mRNA and protein expression, it did induce a muricholate-dominated bile salt pool. Note that 
mRNA and protein levels reflect expression of CYP8B1 at one particular moment during the circadian 















on the other hand provides a physiologically relevant indication of the relative activities of the cholate 
and chenodeoxycholate synthesis pathways over time. We have shown in an earlier study that 
ABCG5/G8-mediated cholesterol efflux in cultured cells is stimulated more strongly by the hydrophilic 
bile salt ursodeoxycholate compared to the more hydrophobic cholate.41 This difference between bile 
salt species now also appears to be of great physiological relevance in vivo. As a matter of fact, our data 
suggest that bile salt species distribution actually underlies the stimulatory effect of PX on FNS excretion 
and TICE (Figure S8).  
Extrapolating our results to humans is complicated by fundamental differences in bile salt synthesis 
between mice and man. While hydrophobic chenodeoxycholate is rapidly converted to hydrophilic 
muricholates in the livers of mice, this additional hydroxylation reaction does not occur in humans. 
Therefore, FXR activation is likely to result in a more hydrophobic bile salt pool in humans, which would 
in theory lead to decreased FNS excretion and TICE. 
In conclusion, this is the first study to demonstrate that the intestine is capable of eliminating very large 
quantities of cholesterol from the body via a direct blood-borne pathway. The flux of cholesterol 
through the TICE pathway is regulated by an interplay between the cholesterol exporter ABCG5/G8 and 
bile salts within the intestinal lumen. In particular, the physical-chemical properties of those luminal bile 
salts appear to play a major role in governing body cholesterol fluxes by impacting on ABCG5/G8 
activity. The current study provides a strong rationale for the consideration of combination therapies 
including hydrophilic bile salts for the management of lipid disorders and protection of atherosclerosis 

















FIGURE 1. Effect of PX20606 on plasma lipids and sterol excretion in wild-type mice  
C57BL/6J mice were treated with 10 mg/kg/day PX20606 (PX), when indicated combined with the 
cholesterol absorption inhibitor ezetimibe (EZE), for 2 wks. (A) Plasma cholesterol and 
(B) triglycerides levels were measured. (C) Fecal bile salt and (D) neutral sterol excretion were assessed 
using gas chromatography. (E) Fractional cholesterol absorption was determined using the appearance 
of stably labeled cholesterol-D5 (i.v.) and cholesterol-D7 (oral) in plasma. (F) Fecal neutral sterol 
excretion during first 8 days of PX treatment measured by gas chromatography. * p<0.05 vs. control 
treated (CTRL) animals, # p<0.05 vs. ezetimibe-treated animals, and $ p<0.05 vs. PX-treated animals (n=7 
mice/group).  
 
FIGURE 2. Sterol fluxes in PX20606-treated mice.  
C57BL/6J mice were treated with 10 mg/kg/day PX20606 (PX), when indicated combined with the 
cholesterol absorption inhibitor ezetimibe (EZE), for 2 wks. At the end of the experiment (A) Bile flow, 
(B) biliary bile salt and (C) biliary cholesterol secretion were determined. (D) Transintestinal cholesterol 
excretion (TICE) was calculated according to the formula TICE=FNS-((Choldiet+Cholbile)*(1-Fa)), where FNS 
means fecal neutral sterols and Fa is fractional cholesterol absorption. (E) Kinetics of intravenously 
administered cholesterol-D5 label as measured by gas chromatography mass-spectrometry (GC-MS). (F) 
Fecal excretion of intravenously injected cholesterol-D5 label calculated by multiplying the enrichment 
of cholesterol-D5 label in feces with mass neutral sterol excretion. * p < 0.05 vs. control treated (CTRL) 
















FIGURE 3: PX20606-induced cholesterol excretion requires intestinal FXR. 
Intestine-specific FXR-deficient (iFXR KO) mice and wild-type (WT) littermates were treated with 10 
mg/kg/day PX20606 (PX), for 2 wks. (A) Fecal neutral sterol excretion determined by gas 
chromatography. (B) Transintestinal cholesterol excretion (TICE). (C) Fractional cholesterol absorption 
determined by dual cholesterol label administration. * p<0.05 vs. control-treated (CTRL) wild-type 
littermates, § p<0.05 vs. wild-type littermates with the same treatment (n=7 mice/group).  
 
FIGURE 4. Reintroduction of intestinal FXR expression in total body FXR-deficient mice restores 
PX20606-induced transintestinal cholesterol excretion   
Total body FXR-KO mice and intestine-specific FXR transgenic (FXR TG) mice were treated with 10 
mg/kg/day PX20606 (PX) for 2 weeks. (A) Plasma cholesterol and (B) plasma triglyceride levels in FXR-KO 
and iFXR-TG mice, measured using commercially available reagents. (C) Fecal neutral sterol excretion in 
FXR-KO and iFXR-TG mice in response to PX treatment determined by gas chromatography. (D) 
Transintestinal cholesterol excretion (TICE). (E) Fractional cholesterol absorption in FXR-KO and iFXR-TG 
mice determined by dual cholesterol label administration. (F) Fecal bile salt excretion measured by gas 
chromatography. * p<0.05 vs. control-treated (CTRL) FXR-KO littermates, § p<0.05 vs. FXR-KO 
littermates with the same treatment (n=6-9 mice/group).  
  
FIGURE 5. Effect of PX20606 and ezetimibe on cholesterol fluxes ABCG8 knock-out mice 
ABCG8-deficient mice and wild-type (WT) littermates were treated with 10 mg/kg/day PX20606 (PX) 















were infected with an ABCG8-encoding (AdABCG8) or control (AdNull) adenovirus as indicated (B-E right 
panels). (A) Hepatic and intestinal mRNA expression of Abcg5 and Abcg8 (left panel) and ABCG5 protein 
expression on brush border membranes isolated from proximal intestinal enterocytes (right panel). (B) 
Fecal neutral sterols determined by gas chromatography. (C) Transintestinal cholesterol excretion (TICE). 
(D) Biliary cholesterol secretion and (E) plasma cholesterol levels measured by gas chromatography. * 
p<0.05 vs. Control (CTRL) treated mice of same genotype; # p<0.05 vs. EZE treated mice of same 
genotype; $ p<0.05 vs. PX treated mice of same genotype; § p<0.05 vs. wild-type or vs. AdNull-injected 
ABCG8 KO with the same treatment (n=3-7 animals per group). ABCG5/G8, ATP binding cassette 
subfamily G member 5/8.  
 
Figure 6. FGF15/19 mediates fecal neutral sterol excretion 
Intestine-specific FXR-deficient (iFXR KO) mice and wild-type (WT) littermates were treated with 10 
mg/kg/day PX20606 (PX), for 2 wks. When indicated, mice were treated with fibroblast growth factor 19 
(FGF19; 1 µg/kg/day, i.p.) during the last 8 days of the experiment. (A) Cholesterol synthesis C57BL/6J 
mice upon PX and PX/ezetimibe (EZE) treatment, determined using the stably labeled precursor 
[13C]acetate. (B) Fecal neutral sterols in iFXR KO mice and WT littermates measured by gas 
chromatography. (C) Gene expression of Cyp7a1 and Cyp8b1 in iFXR-KO mice and WT littermates. (D) 
Biliary bile salt species distribution in iFXR-KO mice and WT littermates determined by gas 
chromatography. (E) Correlation between Heuman’s hydrophobicity index of biliary bile salts and fecal 
neutral sterol excretion in iFXR-KO mice and WT littermates. (F) Biliary bile salt species distribution in 
ABCG8-KO mice, determined as for (D). Parameters from panel A were analyzed in n=7 mice/group. 
Parameters from panels B-F were analyzed in n=3-7 mice/group. * p < 0.05 vs. Control (CTRL) of same 















treatment different genotype; + p < 0.05 vs control-treated with FGF19. α-MCA, α-muricholic acid; β-
MCA, β-muricholic acid; CA, cholic acid; CDCA, chenodeoxycholic acid; CYP7A1, cytochrome P450 family 
7 subfamily A member 1; CYP8B1, cytochrome P450 family 8 subfamily B member 1; DCA, deoxycholic 
acid; HDCA, hyodeoxycholic acid; LCA, lithocholic acid; ω-MCA, ω-muricholic acid; UDCA, 
ursodeoxycholic acid. 
 
FIGURE 7. PX20606-induced fecal neutral sterol excretion is mediated via bile 
Bile duct diversion and model bile infusion was carried out in rats treated with 10 mg/kg/day PX20606 
(PX) for two weeks and controls (CTRL) as detailed in the Methods section. Measurements of neutral 
sterol excretion were performed before and up three days after bile diversion/model bile infusion. (A) 
Biliary bile salt species distribution in PX-treated rats before infusion of model bile determined by gas 
chromatography. (B) Fecal Neutral Sterol excretion before (‘Endogenous bile’) and after bile duct 
diversion/model bile infusion. (C) Hepatic mRNA expression of Cyp7a1, Cyp8b1 and Shp as well as ileal 
Fgf19 mRNA expression after three days of model bile infusion. * p < 0.05 vs. CTRL; $ p < 0.05 vs. PX-
treated rats before bile diversion (n=3-6 rats/group). CYP7A1, cytochrome P450 family 7 subfamily A 
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Figure S1: Hepatic lipids and plasma lipoprotein distribution upon FXR activation with PX20606 
(A) Hepatic cholesterol levels in control (CTRL) mice and mice treated with PX20606 (PX), ezetimibe (EZE) or 
both compounds (PX/EZE). (B) Hepatic triglyceride levels in control mice or mice treated with PX, EZE or both 
compounds. (C) Cholesterol concentration in lipoprotein fractions after separation of pooled plasma samples 
(n=7 animals per group) by fast protein liquid chromatography (FPLC). (D) Triglyceride concentration in 
lipoprotein fractions after separation of pooled plasma samples (n=7 animals per group) by FPLC. * p < 0.05 vs. 
CTRL, $ p < 0.05 vs. PX, # p < 0.05 vs. EZE. HDL, high-density lipoprotein; LDL, low-density lipoprotein; 




















































Figure S2: Alterations of fecal neutral sterol secretion upon treatment with PX20606, ezetimibe or both 
compounds during the 15-day treatment period  
Fecal neutral sterol excretion in C57BL-6J mice measured the first 24h after onset of treatment (feces collected 
on day 1) as well as after 9 and 15 days. Data are presented as mean ± SEM of 7 animals per group. * p<0.05 vs. 
control treated animals, # p<0.05 vs. animals treated with ezetimibe only, $ p<0.05 vs. animals treated with PX 
















Figure S3: Fecal neutral sterols in FXR knock-out mice 
Fecal neutral sterol excretion in wild-type and FXR KO mice after two weeks of treatment with or without 









































Figure S4: Generation of intestine-specific FXR transgenic mice 
(A) Transgene construct of murine FXRα2. The mouse villin promoter was ligated to the murine Fxrα2 gene. 
The construct was restricted from the backbone using PmeI and the resulting villin-FXRα2 fragment was 
quantified for microinjection. (B) Transcriptional activity of murine FXRα2 was tested in response to several 
FXR ligands. A luciferase assay was performed using an luciferase reporter containing tandem copies of FXRE 
from SHP and activity is shown in fold induction. (C) FXR protein expression levels were measured in mucosa 
of the distal ileum of chow-fed FXR KO, iFXR TG and WT mice. FXR protein levels were corrected for 
GAPDH protein levels. Data are presented as means ± SD (n=5 mice/group). (D) Immunohistochemistry 








































Figure S5: KEGG pathways analysis in liver, proximal and distal small intestine 
KEGG pathway analyses of changes in mRNA expression in (A) proximal small intestine, (B) distal small 
intestine and (C) liver after 2 weeks of PX20606 (PX) treatment. (D) Hepatic mRNA expression of Cyp7a1, 
Cyp8b1, and Hmgcr after 2 weeks of treatment with PX or ezetimibe (EZE) determined by QPCR. * p<0.05 vs. 
control treated animals, $ p<0.05 vs. PX-treated animals, and # p<0.05 vs. ezetimibe-treated animals (n=7 
mice/group). CTRL, Control; Cyp7a1, cytochrome P450 family 7 subfamily A member 1; Cyp8b1, cytochrome 
P450 family 8 subfamily B member 1; EZE, ezetimibe; KEGG, Kyoto encyclopedia of genes and genomes; 




































































Figure S6: Fgf15 mRNA expression in the small intestine in response to PX20606 and hepatic CYP8B1 
protein expression in wild-type and intestine-specific FXR KO mice  
(A) Expression of Fgf15 mRNA over the entire length of the small intestine in C57BL-6J mice and controls (n=7 
animals/group). Expression levels were normalized to 36B4. Data are presented as means ± SEM. (B) CYP8B1 
protein expression in livers of WT and intestine-specific FXR knock-out (iFXR KO) mice in response to PX as 
well as CYP8B1 expression in iFXR KO mice treated with FGF19 or PX/FGF19 (n=3-7 mice/group as mean + 


























Figure S7: Change of bile salt species distribution in feces during 8 days of PX treatment 
(A) Fecal bile salt species distribution during 8 days of treatment with PX20606 (n=7 mice/group). α-MCA, α-
muricholic acid; β-MCA, β-muricholic acid; CA, cholic acid; CDCA, chenodeoxycholic acid; CTRL, control; 

















Figure S8: Graphical representation of the proposed mechanism driving the PX20606-induced increase in 
fecal neutral sterol (FNS) excretion and TICE.  
PX20606 (PX) activates FXR in the intestine, leading to the production of FGF15/19 which, in turn, causes a 
shift in bile salt pool composition towards more hydrophilic bile salts. At the level of the enterocyte, excretion of 
cholesterol from the cell into the intestinal lumen is induced in a manner that largely depends on the activity of 
ABCG5/G8. As the amount of ABCG5/G8 protein on the brush border membrane remains unchanged upon PX-
treatment, the transport activity must be increased. Hydrophilic bile salts may facilitate increased export of 
cholesterol from enterocytes by ABCG5/G8. When re-uptake of exported cholesterol is blocked by addition of 













Supplementary Experimental Procedures 
 
 
Hepatic lipid extraction 
Liver lipids were extracted from homogenates according to Bligh and Dyer.1 Subsequently, hepatic cholesterol 
and triglyceride content was determined using commercially available reagents (DiaSys Diagnostic Systems, 
Holzheim, Germany and Roche Diagnostics, Mannheim, Germany).  
 
Plasma lipoprotein separation 
Separation of lipoproteins was performed using fast protein liquid chromatography (FPLC) applying a Superose-
6 10/300 GL column (GE Healthcare, Uppsala, Sweden) as described previously.2 Cholesterol and triglyceride 
concentrations in the individual fractions were determined using commercially available reagents (DiaSys 
Diagnostic Systems and Roche Diagnostics). 
 
Plasmid construction and generation of intestine-specific FXRα2 mice 
The coding sequences of murine FXRα2 was amplified using specific primer pairs (forward; 
TACTACGGATCCACCATGAATCTGATTGGGGACTCC, reverse; TACTACGCGGCCGCTCACTGCACAT 
CCCAGATCT) harboring a Kozak consensus ATG initiation codon and a BamH1 restriction side at the 5’ end 
and a Not1 restriction side at the 3’ end. As a template source, cDNA was synthesized from hepatic RNA from 
C57BL/6J mice. The products were cloned into pcDNA5/FRT/TO (Life Technologies, Bleiswijk, The 
Netherlands). The presence of the correct gene was sequence-verified. Subsequently, the MYTG insertion was 
deleted from FXRα1 using inverse PCR primers (forward; TTGTTAACTGAAATCCAGTG, reverse; 
ACATTCAGCCAACATCCCCA), to generate FXRα2. FXRα2 was cloned behind the villin promoter in the 
pBSII-12.4kbVillin plasmid3 (kind gift from Deborah Gumucio, University of Michigan Medical School, Ann 
Arbor MI, USA). FXRα2 was restricted from pCDNA5/FRT/TO using PmeI and XhoI and was ligated into the 
12.4 kbVillin plasmid restricted using SmaI and XhoI. The presence of the correct insert and orientation was 
sequence-verified. Subsequently, the vector backbone was deleted by restriction using PmeI in the 12.4 kbVillin 
plasmid. The linear Villin-FXRα2 sequence was heat-inactivated and purified using gel electrophoresis. 
Intestine-specific murine-FXRα2 transgenic mice were generated by microinjection of the construct into 
fertilized FVB/NHsd eggs. Clones with the highest murine FXR mRNA expression levels were recovered. Mice 
were backcrossed to whole body FXR-deficient mice4, on a C57BL/6J background, generating a model with 
intestine-specific expression of FXRα2 on a whole-body FXR knock-out background. 
 
Cell culture, transfections and reporter assays 
CV1 cells (a kind gift from Ronald M. Evans, Salk Institute, San Diego, USA) were maintained in DMEM 
(Gibco, Breda, The Netherlands) supplemented with 10% FCS (Sigma Aldrich Chemie BV, Zwijndrecht, The 
Netherlands), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco, Breda, The Netherlands). Cultures were 
maintained at 37°C and 5% CO2 in a humidified incubator. Cells were transiently transfected using FuGENE 6 
transfection reagent (Promega, Leiden, The Netherlands). Cell lysis and luciferase assay were performed using a 
dual luciferase reporter assay system (Promega, Leiden, The Netherlands). Briefly, the human PGL4-SHP 
(CHR16_M0432_R1 and CHR1_M0312_R1, Switchgear Genomics, Menlo Park, CA, USA) promoter reporter 
was transfected together with the pcDNA5/FRT/TO vector containing murine FXR and RXR alpha/NR2B1 for 
48 hrs. Cells remained untreated or were treated with 50µM CDCA (Sigma-Aldrich), 1µM GW4064 (Sigma-
Aldrich) or 1µM PX5,6 (Phenex Pharmaceuticals, Heidelberg, Germany) 24 prior to cell lysis. 
 
Intestinal immunohistochemical protein expression of FXR 
Briefly, after fixation in formaldehyde, intestinal pieces were embedded in paraffin and cut into 4µm sections. 
For immunohistochemistry, sections were deparaffinized and rehydrated. Antigen-retrieval was done in 0.01 M 
citrate buffer pH 6 at 100°C for 20 min. Endogenous peroxidase activity was blocked by incubation for 30 min 
in 3% H2O2 in phosphate-buffered saline (PBS). Sections were blocked with 5% goat serum in PBS for 30 min. 
Immunostaining was performed overnight at 4°C using anti-FXR (Perseus Proteomics, Tokyo, Japan; PP-
A9033A-00) 0.01 mg/ml in 2% normal goat serum/1% bovine serum albumin in PBS. Sections were washed in 
PBS followed by a 60 min incubation with polyclonal goat anti-mouse immunoglobulins/biotinylated (Dako, 
Denmark; 1/200 dilution), and subsequent by a 60 min incubation with streptavidin/HRP (Dako, Denmark; 1/200 
dilution), both in PBS containing 1% normal goat serum. Visualization of the immune complexes was performed 
with diaminobenzidine, followed by hematoxylin counterstaining for 60 sec. Sections were dehydrated and 
mounted with Eukitt (Sigma-Aldrich, USA). 
 













Intestinal mucosa was homogenized in buffer containing 50 mM Tris (pH 7.4), 300 mM sucrose, 10 mM EDTA, 
10 mM DTT and protease inhibitors (Complete; Roche Diagnostics, Almere, The Netherlands). Protein was 
determined using BCA protein assay (Pierce Biotechnology, Rockford, IL, USA). Intestinal homogenates (25 µg 
protein) for detection of FXR were electrophoresed through 7% polyacrylamide gels and blotted on Hybond 
ECL membranes (Amersham, Little Chalfont, UK). Membranes were blocked in phosphate-buffered saline (pH 
7.4) containing 0.1% Tween 20 and 4 % skim milk powder. Membranes were incubated with anti-FXR antibody 
(clone no. A9033A, Perseus Proteomics Inc., Tokyo, Japan). After washing, immunocomplexes were detected 
using horseradish peroxidase-conjugated goat anti-mouse IgG2a (Southern Biotech, Uithoorn, The Netherlands) 
and SuperSignal West Dura substrate (Thermo Scientific, Rockford, IL, USA). 
 
Microarray Analyses 
For microarray analyses, total hepatic and proximal and distal intestinal RNA was prepared from C57BL/6J mice 
(n =4-6 per group) receiving diet with or without supplementation of 10 mg/kg/day PX20606, using TRI-reagent 
(Sigma-Aldrich, St. Louis, MO, USA). RNA quality and concentration was assessed using a Biorad Experion 
Bioanalyzer. Starting with 200 ng of RNA, with an RNA Quality Indicator of at least 8, RNA was amplified and 
labeled using the Illumina TotalPrep RNA Amplification Kit (Applied Biosystems, Nieuwekerk a/d IJssel, The 
Netherlands). The WG-6 v2 expression arrays, containing 45281 transcripts (Illumina, San Diego, USA), were 
processed according to the manufactures protocol and slides were scanned immediately. Quality control, 
normalization (quantile), batch correction (Combat), and statistics (IBMT) were performed in MADMAX.7 A 
list of significantly changed annotated genes between PX (n = 4) and WT (n = 4), including False Discovery 
Rates (FDR)-corrected p-values (5% or 10%) was generated. All microarray data reported are described in 
accordance with MIAME guidelines and are available in the GEO (GSE74101). Identification of overrepresented 
functional categories and enrichment analysis among responsive genes and their grouping into functionally 
related clusters was performed using the DAVID Functional Annotation Clustering tool8 and GSEA.9  
Reviewers link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=irsrayeohfcntqx&acc=GSE74101 
Quantification of CYP8B1 protein expression 
Targeted proteomics10 was used to quantify CYP8B1 in homogenized liver tissue via the isotopically labeled 
peptide standard VVQEDYVLK, containing 13C-labeled lysine (PolyQuant GmbH, Germany). Briefly, 
homogenized tissues (50 µg protein) were mixed with 3.22 fmol of standard peptide per 1 µg of total protein. In-
gel tryptic digestion (1:100 g/g sequencing grade modified trypsin V5111, Promega) was performed after 
reduction with 10 mM dithiothreitol and alkylation with 55 mM iodoacetamide proteins, followed by solid phase 
extraction (SPE C18-Aq 50 mg/1mL, Gracepure) for sample cleanup. The peptide was targeted and analyzed by 
a triple quadrupole mass spectrometer (MS) equipped with a nano-electrospray ion source (TSQ Vantage, 
Thermo Scientific). Chromatographic separation was performed by liquid chromatography on a nano-UHPLC 
system (Ultimate UHPLC focused, Dionex) using a nano column (Acclaim PepMap100 C18, 75 µmx500mm 
2µm, 100 Å) with a linear gradient from 3-60 % v/v acetonitrile plus 0.1% v/v formic acid in 110 minutes at a 
flowrate of 200 nL/min. The MS traces were manually curated using the Skyline software11 prior to integration 
of the peak areas for quantification. The concentration of the endogenous peptide was calculated from the known 
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